{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:29:14Z","timestamp":1761823754745},"reference-count":74,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2015,8,10]],"date-time":"2015-08-10T00:00:00Z","timestamp":1439164800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cathet Cardio Intervent"],"published-print":{"date-parts":[[2016,4]]},"abstract":"<jats:p>Dual antiplatelet therapy reduces the risk of myocardial infarction, stent thrombosis, and cardiovascular mortality after percutaneous coronary intervention, but the optimal duration of therapy remains unclear. Stent thrombosis, one of the most feared complications of coronary intervention, is associated with high mortality and morbidity and is related in part to technical and patient\u2010specific factors. Advances in device technology and better understanding of the pathophysiology of stent thrombosis have reduced the frequency of this devastating complication. Bioresorbable vascular scaffolds possess a number of advantageous features and are currently undergoing active investigation. Bioresorbable vascular scaffolds have been demonstrated to restore physiologic vasomotion, allow for late lumen enlargement, and upon full resorption remove the nidus for very late polymer reactions and resolve concerns of stent malapposition and side branch jailing. Based on the results from recent large\u2010scale randomized trials, the optimal duration of dual antiplatelet therapy may depend on the choice of device type, as well as the individual patient risk of ischemic versus hemorrhagic complications. \u00a9 2015 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/ccd.26099","type":"journal-article","created":{"date-parts":[[2015,8,10]],"date-time":"2015-08-10T11:03:35Z","timestamp":1439204615000},"page":"909-919","source":"Crossref","is-referenced-by-count":2,"title":["Dual antiplatelet therapy, drug\u2010eluting stents and bioresorbable vascular scaffolds: Evolutionary perspectives"],"prefix":"10.1002","volume":"87","author":[{"given":"Felipe N.","family":"Albuquerque","sequence":"first","affiliation":[{"name":"Division of Cardiovascular Diseases\u2014Montefiore Medical Center Albert Einstein College of Medicine New York New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Bortnick","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Diseases\u2014Montefiore Medical Center Albert Einstein College of Medicine New York New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javaid","family":"Iqbal","sequence":"additional","affiliation":[{"name":"ThoraxCenter Erasmus University Medical Center Rotterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Ishibashi","sequence":"additional","affiliation":[{"name":"ThoraxCenter Erasmus University Medical Center Rotterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregg W.","family":"Stone","sequence":"additional","affiliation":[{"name":"Columbia University Medical Center\/New York\u2010Presbyterian Hospital New York New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick W.","family":"Serruys","sequence":"additional","affiliation":[{"name":"ThoraxCenter Erasmus University Medical Center Rotterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,8,10]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/3218"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra071014"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa010746"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/35051599"},{"key":"e_1_2_6_6_1","doi-asserted-by":"crossref","unstructured":"SteinhublSR BergerPB MannJT III FryET DeLagoA WilmerC TopolEJ.Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. J Am Med Assoc2002;288:2411\u20132420.","DOI":"10.1001\/jama.288.19.2411"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.95.5.1145"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.100.15.1667"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000130846.46168.03"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706482"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904327"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.2002"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908629"},{"key":"e_1_2_6_14_1","doi-asserted-by":"crossref","unstructured":"WhiteHD ChewDP DauermanHL MahaffeyKW GibsonCM StoneGW GrubergL HarringtonRA BhattDL.Reduced immediate ischemic events with cangrelor in PCI: A pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction. Am Heart J2012;163:182\u2013190 e184.","DOI":"10.1016\/j.ahj.2011.11.001"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1300815"},{"key":"e_1_2_6_16_1","unstructured":"MegaJL SimonT ColletJP AndersonJL AntmanEM BlidenK CannonCP DanchinN GiustiB GurbelP HorneBD HulotJS KastratiA MontalescotG NeumannFJ ShenL SibbingD StegPG TrenkD WiviottSD SabatineMS.Reduced\u2010function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: A meta\u2010analysis. J Am Med Assoc2010;304:1821\u20131830."},{"key":"e_1_2_6_17_1","unstructured":"MegaJL HochholzerW FrelingerAL III KlukMJ AngiolilloDJ KereiakesDJ IssermanS RogersWJ RuffCT ContantC PencinaMJ SciricaBM LongtineJA MichelsonAD SabatineMS.Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. J Am Med Assoc2011;306:2221\u20132228."},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.029165"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2013.105"},{"key":"e_1_2_6_20_1","doi-asserted-by":"crossref","unstructured":"SilvainJ CaylaG HulotJS FinziJ KerneisM O'ConnorSA Bellemain\u2010AppaixA BarthelemyO BeyguiF ColletJP MontalescotG.High on\u2010thienopyridine platelet reactivity in elderly coronary patients: the SENIOR\u2010PLATELET study. Eur Heart J2012;33:1241\u20131249.","DOI":"10.1093\/eurheartj\/ehr407"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehn362"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)62177-1"},{"key":"e_1_2_6_23_1","doi-asserted-by":"crossref","unstructured":"LatibA IelasiA FerriL ChieffoA GodinoC CarlinoM MontorfanoM ColomboA.Aspirin intolerance and the need for dual antiplatelet therapy after stent implantation: A proposed alternative regimen. Int J Cardiol2013;165:444\u2013447.","DOI":"10.1016\/j.ijcard.2011.08.080"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht438"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu031"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1001266"},{"key":"e_1_2_6_27_1","first-page":"2015","article-title":"Prolonging Dual Antiplatelet Treatment After Grading Stent\u2010Induced Intimal Hyperplasia Study I","volume":"125","author":"Valgimigli M","year":"2012","journal-title":"Short\u2010 versus long\u2010term duration of dual\u2010antiplatelet therapy after coronary stenting: A randomized multicenter trial. Circulation"},{"key":"e_1_2_6_28_1","doi-asserted-by":"crossref","unstructured":"Task ForceM MontalescotG SechtemU AchenbachS AndreottiFArdenC. BudajA BugiardiniR CreaF CuissetT DiMarioC FerreiraJR GershBJ GittAK HulotJS MarxN OpieLHPfistererM PrescottE RuschitzkaF SabateM SeniorR TaggartDP van derWallEE VrintsCJ Guidelines ESCCfP ZamoranoJL AchenbachS BaumgartnerH BaxJJ BuenoH DeanV DeatonC ErolC FagardR FerrariR HasdaiD HoesAW KirchhofP KnuutiJ KolhP LancellottiP LinhartA NihoyannopoulosP PiepoliMF PonikowskiP SirnesPA TamargoJL TenderaM TorbickiA WijnsW WindeckerS DocumentR KnuutiJ ValgimigliM BuenoH ClaeysMJ Donner\u2010BanzhoffN ErolC FrankH Funck\u2010BrentanoC GaemperliO Gonzalez\u2010JuanateyJR HamilosM HasdaiD HustedS JamesSK KervinenK KolhP KristensenSD LancellottiP MaggioniAP PiepoliMF PriesAR RomeoF RydenL SimoonsML SirnesPA StegPG TimmisA WijnsW WindeckerS YildirirA ZamoranoJL.2013 ESC guidelines on the management of stable coronary artery disease: The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J2013;34:2949\u20133003.","DOI":"10.1093\/eurheartj\/eht296"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu523"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.059022"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.06.043"},{"key":"e_1_2_6_32_1","first-page":"2510","article-title":"Three vs. twelve months of dual antiplatelet therapy after zotarolimus\u2010eluting stents: the OPTIMIZE randomized trial","volume":"310","author":"Feres F","year":"2013","journal-title":"J Am Med Assoc"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.12.055"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.686048"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.23438"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehq277"},{"key":"e_1_2_6_37_1","unstructured":"ColomboA ChieffoA FrasheriA GarboR MasottiM SalvatellaN Oteo DominguezJF SteffanonL TarantiniG PresbiteroP MenozziA PucciE MauriJ CesanaBM GiustinoG SardellaG.Second generation drug\u2010eluting stents implantation followed by six versus twelve\u2010month \u2010 Dual antiplatelet therapy\u2010 The SECURITY Randomized Clinical Trial. J Am Coll Cardiol2014;64:2086\u20132097."},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.003303"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2010.09.029"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-14-56"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61720-1"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199408253310801"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.003210"},{"key":"e_1_2_6_44_1","doi-asserted-by":"crossref","unstructured":"IakovouI SchmidtT BonizzoniE GeL SangiorgiGM StankovicG AiroldiF ChieffoA MontorfanoM CarlinoM MichevI CorvajaN BriguoriC GerckensU GrubeE ColomboA.Incidence predictors and outcome of thrombosis after successful implantation of drug\u2010eluting stents. J Am Med Assoc2005;293:2126\u20132130.","DOI":"10.1001\/jama.293.17.2126"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.666800"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.685313"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.683995"},{"key":"e_1_2_6_48_1","doi-asserted-by":"crossref","unstructured":"HolmesDR Jr KereiakesDJ GargS SerruysPW DehmerGJ EllisSG WilliamsDO KimuraT MoliternoDJ.Stent thrombosis. J Am Coll Cardiol2010;56:1357\u20131365.","DOI":"10.1016\/j.jacc.2010.07.016"},{"key":"e_1_2_6_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jjcc.2011.07.004"},{"key":"e_1_2_6_50_1","doi-asserted-by":"crossref","unstructured":"OngAT McFaddenEP RegarE deJaegerePP vanDomburgRT SerruysPW.Late angiographic stent thrombosis (LAST) events with drug\u2010eluting stents. J Am Coll Cardiol2005;45:2088\u20132092.","DOI":"10.1016\/j.jacc.2005.02.086"},{"key":"e_1_2_6_51_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.803627"},{"key":"e_1_2_6_52_1","doi-asserted-by":"crossref","unstructured":"JonerM FinnAV FarbA MontEK KolodgieFD LadichE KutysR SkorijaK GoldHK VirmaniR.Pathology of drug\u2010eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol2006;48:193\u2013202.","DOI":"10.1016\/j.jacc.2006.03.042"},{"key":"e_1_2_6_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540-8183.2007.00312.x"},{"key":"e_1_2_6_54_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.058560"},{"key":"e_1_2_6_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2013.05.005"},{"key":"e_1_2_6_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2013.04.011"},{"key":"e_1_2_6_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)62127-9"},{"key":"e_1_2_6_58_1","unstructured":"CamenzindE BoersmaE WijnsW MauriL Rademaker\u2010HavingaT OrdoubadiFF SuttorpMJ KurdiMA StegPG;PROTECT Steering Committee and Investigators.Modifying effect of dual antiplatelet therapy on incidence of stent thrombosis according to implanted drug\u2010eluting stent type. Eur Heart J2014;35:1932\u20131948."},{"key":"e_1_2_6_59_1","doi-asserted-by":"publisher","DOI":"10.4244\/EIJV5IFA1"},{"key":"e_1_2_6_60_1","first-page":"70","article-title":"Biodegradable stents: they do their job and disappear","volume":"18","author":"Waksman R.","year":"2006","journal-title":"J Invasive Cardiol"},{"key":"e_1_2_6_61_1","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-10-1135"},{"key":"e_1_2_6_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2011.02.008"},{"key":"e_1_2_6_63_1","doi-asserted-by":"crossref","unstructured":"SerruysPW OnumaY DudekD SmitsPC KoolenJ ChevalierB deBruyneB ThuesenL McCleanD vanGeunsRJ WindeckerS WhitbournR MeredithI DorangeC VeldhofS HebertKM SudhirK Garcia\u2010GarciaHM OrmistonJA.Evaluation of the second generation of a bioresorbable everolimus\u2010eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12\u2010month clinical and imaging outcomes. J Am Coll Cardiol2011;58:1578\u20131588.","DOI":"10.1016\/j.jacc.2011.05.050"},{"key":"e_1_2_6_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2010.07.016"},{"key":"e_1_2_6_65_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.109.859173"},{"key":"e_1_2_6_66_1","first-page":"301","article-title":"The ABSORB bioresorbable vascular scaffold: An evolution or revolution in interventional cardiology?","volume":"53","author":"Gogas BD","year":"2012","journal-title":"Hellenic J Cardiol"},{"key":"e_1_2_6_67_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.000901"},{"key":"e_1_2_6_68_1","doi-asserted-by":"publisher","DOI":"10.1159\/000159144"},{"key":"e_1_2_6_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60325-1"},{"key":"e_1_2_6_70_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10554-009-9567-6"},{"key":"e_1_2_6_71_1","doi-asserted-by":"publisher","DOI":"10.4244\/EIJV10I12A243"},{"key":"e_1_2_6_72_1","doi-asserted-by":"publisher","DOI":"10.4244\/EIJY14M07_11"},{"key":"e_1_2_6_73_1","article-title":"Definite and probable bioresorbable scaffold thrombosis in stable and ACS patients","author":"Ishibashi Y","year":"2014","journal-title":"EuroIntervention"},{"key":"e_1_2_6_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61455-0"},{"key":"e_1_2_6_75_1","unstructured":"DilettiR SerruysPW FarooqV SudhirK DorangeC Miquel\u2010HebertK VeldhofS RapozaR OnumaY Garcia\u2010GarciaHM ChevalierB.ABSORB II randomized controlled trial: A clinical evaluation to compare the safety efficacy and performance of the Absorb everolimus\u2010eluting bioresorbable vascular scaffold system against the XIENCE everolimus\u2010eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design. Am Heart J2012;164:654\u2013663."}],"container-title":["Catheterization and Cardiovascular Interventions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fccd.26099","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fccd.26099","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ccd.26099","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T18:25:23Z","timestamp":1695493523000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ccd.26099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,10]]},"references-count":74,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["10.1002\/ccd.26099"],"URL":"https:\/\/doi.org\/10.1002\/ccd.26099","archive":["Portico"],"relation":{},"ISSN":["1522-1946","1522-726X"],"issn-type":[{"value":"1522-1946","type":"print"},{"value":"1522-726X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,10]]}}}